Gilead Sciences | GILD - Ebit





Ebit Alterar Data
AbbVie USD 6.88B 156M 2026-09
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
ALKERMES USD 36.59M 102.52M 2026-09
Alnylam Pharmaceuticals USD 179.66M 67.06M 2026-09
Amgen USD 4.68B 65M 2026-09
Biogen USD 419.5M 663.3M 2026-09
BioMarin Pharmaceutical USD 205.6M 100M 2026-09
Bristol-Myers Squibb USD 255M 44M 2026-09
Coherus Biosciences USD -39.08M 3.65M 2025-12
Eli Lilly USD 13.09B 635M 2026-09
Gilead Sciences USD 3.85B 1.17B 2026-06
GlaxoSmithKline GBP 2.86B 251M 2026-09
Glaxosmithkline GBP 2.15B 157M 2026-09
Incyte USD -707.47M 1.41B 2026-09
J&J USD 6.47B 1B 2026-09
Merck USD 7.33B 6.49B 2026-09
Moderna USD -815M 573M 2026-06
Neurocrine Biosciences USD 343M 123.1M 2026-09
Novartis USD 5.14B 411M 2026-09
Pfizer USD 4.85B 5.03B 2026-09
PTC Therapeutics USD 146.03M 100.14M 2026-06
Puma Biotechnology USD -2.2M 11.41M 2024-06
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Sanofi EUR 4.72B 3.6B 2026-09
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
United Therapeutics USD 375.6M 49.8M 2026-06
Vertex Pharmaceuticals USD 1.26B 11.3M 2026-09